In a patient with suspected acute pulmonary embolism who has received tenecteplase (Metalyse) and therapeutic heparin infusion, what vital signs, neurologic status, bleeding signs, and laboratory values should be monitored?

Monitoring After Tenecteplase and Heparin for Suspected Pulmonary Embolism

You must closely monitor for bleeding complications, hemodynamic status, and coagulation parameters, with particular attention to signs of hemorrhage given the 10-40% bleeding risk with thrombolytic therapy. 1, 2

Critical Bleeding Surveillance

Monitor continuously for any signs of hemorrhage, as this is the major life-threatening complication of combined thrombolytic and anticoagulant therapy:

• Neurologic status: Perform frequent neurologic assessments (at minimum every 1-2 hours initially) to detect intracranial hemorrhage, which occurs in approximately 1% of thrombolysis patients 3
• Visible bleeding sites: Examine for bleeding from IV sites, surgical wounds, gastrointestinal tract (hematemesis, melena, hematochezia), urinary tract (hematuria), and any recent puncture sites 1
• Internal bleeding indicators: Monitor for signs of retroperitoneal bleeding (flank pain, unexplained hypotension), hemoptysis, or hemopericardium 1
• High-risk patients require intensified surveillance: Those with recent surgery (within 7 days), peptic ulcer disease, or platelet counts <150 × 10⁹/L have 10% major bleeding risk versus 1% in low-risk patients 1

Hemodynamic Monitoring

Continuous cardiovascular monitoring is essential to assess treatment response and detect deterioration:

• Blood pressure: Measure continuously or every 15 minutes initially, looking for resolution of hypotension (goal systolic BP >90 mmHg) or new hypotension suggesting bleeding 3
• Heart rate and rhythm: Continuous cardiac telemetry to detect arrhythmias and assess tachycardia resolution 3
• Oxygen saturation: Continuous pulse oximetry, with improvement expected as pulmonary perfusion improves 3
• Vasopressor requirements: If patient was on inotropic support, monitor for ability to wean (typically begins 1-14 hours post-thrombolysis) 2, 4

Laboratory Monitoring

Serial coagulation and hematologic parameters must be tracked:

APTT Monitoring for Heparin Dosing

• First APTT: Draw 4-6 hours after initiating heparin infusion (which should be started 3 hours after tenecteplase completion) 1, 2
• Target APTT: 1.5-2.5 times control (45-75 seconds) 1
• After dose adjustments: Recheck APTT 6-10 hours after any infusion rate change 1
• Once therapeutic: Daily APTT monitoring 1

Platelet Count Monitoring

• Monitor platelet count if heparin is continued beyond 5 days due to risk of heparin-induced thrombocytopenia with thrombosis 1
• Baseline and serial measurements are prudent even in the first 5 days given the prothrombotic risk 1

Hemoglobin/Hematocrit

• Serial complete blood counts to detect occult bleeding, particularly if patient becomes hemodynamically unstable or shows signs of anemia 1

Respiratory Status Assessment

Monitor for improvement in respiratory function:

• Respiratory rate: Should decrease from initial tachypnea (most PE patients have rate >20/min) 1
• Oxygen requirements: Track FiO₂ needs and ability to wean supplemental oxygen 3
• Dyspnea severity: Subjective improvement typically occurs within hours of successful thrombolysis 3

Right Ventricular Function Assessment

Follow-up echocardiography provides objective evidence of treatment success:

• RV/LV ratio: Should improve within 24-48 hours post-thrombolysis; failure to improve suggests treatment failure 2
• RV dysfunction resolution: Thrombolysis significantly reduces persistent RV dysfunction compared to heparin alone 3
• Timing: Consider repeat echocardiography at 24-48 hours to document improvement 2

Clinical Response Timeline

Expected clinical improvements occur rapidly with successful thrombolysis:

• 1-14 hours post-tenecteplase: Vasopressor weaning typically begins 2, 4
• 24 hours: Significant improvement in RV function and hemodynamics should be evident 2
• 30 minutes post-bolus: If 50 mg bolus was given for cardiac arrest, reassess for return of spontaneous circulation 2

Critical Pitfalls to Avoid

• Do not restart heparin during the 2-hour tenecteplase infusion if it was given as an infusion; wait 3 hours after completion 2, 3
• Do not ignore subtle neurologic changes: Any altered mental status, headache, or focal deficit mandates immediate CT head to rule out intracranial hemorrhage 1
• Do not assume therapeutic APTT without checking: Weight-adjusted heparin dosing (18 IU/kg/hour maintenance) achieves therapeutic levels more quickly but still requires confirmation 1, 2
• Do not delay intervention for major bleeding: Have reversal agents readily available (protamine for heparin) and be prepared for emergent transfusion 1